¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"heparin therapy monitoring"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® fetal monitoring ÇÑ±Û Å¾ư¨½Ã
¼³¸í   
  ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀǠžÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» Å¾ư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü Å¾ư¨½Ã¿Í ºÐ¸¸Áߠžư¨½Ã·Î Å©°Ô ³ª´«´Ù.
  
  1. ºÐ¸¸Àü Å¾ư¨½Ã´Â ºÐ¸¸Çϱâ ÀÌÀüÀǠžÆÀÇ »óŸ¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù.
  
    1)¾ç¼öõÀÚ-ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼­ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼­ ¾ç¼ö¸¦ ¾ò¾î¼­ ºÐ¼®ÇÏ¿© Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼­ ½Ç½ÃÇÒ ¼ö°¡ ÀÖ´Ù.
  
    2)ÅÈÁÙõÀÚ-ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼­ ÅÈÁÙ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼­ ±×°÷ÀÇ Ç÷°üÀ» Ã£¾Æ Ç÷¾×À» Ã¤ÃëÇÏ¿© °Ë»çÇϴ ¹æ¹ý.
  
    3)½ºÆ®·¹½º°Ë»ç-žƵµ Àڱüӿ¡¼­ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î Å¾ư¡ Àڱüӿ¡¼­ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â Å¾ÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. Å¾ÆÀÇ ¿îµ¿°ú Å¾ÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ Å¾ÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù.
  
    4)žÆÃ»°¢Àڱذ˻ç-30ÁÖ ÀÌ»óÀÌ µÈ Å¾ƴ ¼Ò¸®ÀÇ Àڱؿ¡ ´ëÇØ¼­ ¹ÝÀÀÀ» ÇÑ´Ù. Áï ¼Ò¸®¸¦ µé·ÁÁÖ¾úÀ» °æ¿ì¿¡ Å¾ư¡ ¹ÝÀÀÀ» Çؼ­ ½ÉÀåÀÇ ¹Úµ¿¼ö°¡ Áõ°¡¸¦ ÇÑ´Ù.
  
    5)¼öÃེƮ·¹½º°Ë»ç-Á¤»óÀûÀΠžƴ ÀÚ±ÃÀÌ ¼öÃàÇϸé ÀÌ¿¡ ¹ÝÀÀÀ» Çؼ­ ½É¹Ú¼ö°¡ º¯È­ÇÑ´Ù. À̰ÍÀ» ÀÌ¿ëÇÏ¿© Å¾ÆÀÇ »óŸ¦ °Ë»çÇϴ ¹æ¹ýÀÌ´Ù.
  
  2. ºÐ¸¸Áߠžư¨½Ã
  
  ºÐ¸¸µµÁß¿¡ Å¾ÆÀÇ °Ç°­»óŸ¦ °¨½ÃÇϴ °ÍÀÌ´Ù. ´ëü·Î ºÐ¸¸µµÁß¿¡ Å¾ư¡ Àú»ê¼ÒÁõÀ̳ª ¿©·¯ °¡Áö Ãæ°ÝÀ» ¹Þ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î ºÐ¸¸µµÁßÀǠžư¨½Ã´Â Áß¿äÇÑ Àǹ̸¦ °¡Áø´Ù.
  
    1)ÀüÀڽĞư¨½Ã-Àü±âÀû ÀåÄ¡¸¦ ÀÌ¿ëÇÏ¿© Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ¸·Î °¨½ÃÀÇ ´ë»óÀº ÀÚ±ÃÀÇ ¼öÃà°ú Å¾ÆÀÇ ½ÉÀå¹Úµ¿¼öÀÌ´Ù.
  
    2)žƸӸ®µ¤°³ Ç¥º»Ã¤Ãë Ç÷¾×-ºÐ¸¸µµÁß¿¡ Å¾ÆÀÇ µÎÇÇÀÇ Ç÷°ü¿¡¼­ Ç÷¾×À» Ã¤ÃëÇÏ¿© °Ë»ç¸¦ ÅëÇØ¼­ Å¾ÆÀÇ »óŸ¦ ¾Æ´Â ¹æ¹ýÀÌ´Ù. ÁַΠ°Ë»ç¸¦ ÇàÇϴ Á¾¸ñÀº Ç÷¾×ÀÇ pHÀÌ´Ù.
¿µ¹® heparin ÇÑ±Û ÇìÆÄ¸°
¼³¸í   
  Ç÷¾× ÀÀ°í¸¦ ¸·´Â ÀÛ¿ëÀ» Çϴ ´Ù´ç·ùÀǠȲ»ê¿¡½ºÅ׸£. °íµîµ¿¹°ÀÇ °¢Á¾ Á¶Á÷¿¡ ³Î¸® ºÐÆ÷µÇ¾î ÀÖÀ¸¸ç, ¼ö¼ú ÈÄÀÇ Ç÷ÀüÁõÀ» ¸·´Â µ¥ ¾´´Ù. Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò´Â ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹­´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼­ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. ÀÌ ¼¶À¯¼Ò´Â Æ®·Òºó¿¡ ÀÇÇØ ¼¶À¯¼Ò¿ø¿¡¼­ ÀüȯµÈ´Ù. ÇìÆÄ¸°À̶ó´Â ¹°ÁúÀº ÀÌ Æ®·ÒºóÀ» ¾ïÁ¦Çϴ Çׯ®·ÒºóÀ» È°¼ºÈ­Çϴ ¹°ÁúÀÌ´Ù.
  
  
¿µ¹® family therapy ÇÑ±Û °¡Á·¿ä¹ý
¼³¸í   
  °¡Á·À» Ä¡·á ´ë»óÀ¸·Î Çϴ ½É¸®¿ä¹ý ÁßÀÇ Çϳª. °¡Á·ÁßÀÇ ¹®Á¦´Â ¹®Á¦¸¦ °¡Áø °³Àθ¸ÀÌ ¾Æ´Ï¶ó ¹®Á¦ °¡Á·À» ´ë»óÀ¸·Î ÇذáÇØ ³ª°¥ Çʿ䰡 Àִٴ ÀνÄÀ» ¹ÙÅÁÀ¸·Î ÇÏ¿© °¡Á· ÀüüÀÇ ½É¸®Àû ¼º¼÷À» ¸ñÇ¥·Î ÇÑ ¿ä¹ýÀÌ´Ù. Å©°Ô ³ª´©¾î °¡Á· ÁßÀǠƯÁ¤ÀÎÀ» ´ë»óÀ¸·Î ÇÏ¿© °¢°¢ ´Ù¸¥ µ¶¸³µÈ Ä¡·á¸¦ Çϴ º´Çà½É¸®¿ä¹ý°ú °¡Á· Àüü¸¦ µ¿½Ã ¸éÁ¢Çϴ ¹æ¹ýÀ» ÁַΠÇϴ ÇÕµ¿°¡Á·¿ä¹ýÀÌ Àִµ¥, Æ¯È÷ ÈÄÀÚ¸¦ °¡¸®ÄÑ °¡Á·¿ä¹ý À̶ó°í Çϴ °æ¿ì°¡ ¸¹´Ù.
¿µ¹® intracavitary therapy ÇÑ±Û °­³»¿ä¹ý
¼³¸í   
  Ã¼°­³», Áï ÀÔ¾È, ÄÚ¾È, Àεΰ­, ½Äµµ, °ðâÀÚ, Áú, Àڱøñ, ¹æ±¤ µîÀÇ ³»°­¿¡, ¶§·Î´Â º´ÅÍ¿¡ ÀÇÇØ »ý±ä °øµ¿³»¿¡ ¹æ»ç¼±À» »ðÀÔÇØ¼­ Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. ÁַΠÁ¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ´Ù.
¿µ¹® hyperbaric oxygenation therapy ÇÑ±Û °í¾Ð»ê¼Ò¿ä¹ý
¼³¸í   
  ´ë±â¾Ðº¸´Ù ³ôÀº ±â¾Ðȯ°æÀ» ÀΰøÀûÀ¸·Î ¸¸µé¾î ±× ¾È¿¡¼­ °í³óµµÀÇ »ê¼Ò¸¦ ÈíÀÔ½Ã۴ ¿ä¹ý. Çѱ¹¿¡¼­ ¿¬Åº°¡½º·Î ´ëÇ¥µÇ´Â ÀÏ»êȭź¼ÒÀÇ ±Þ¼ºÁßµ¶ÀÇ Ä¡·á¿¡ ¸¹ÀÌ ÀÌ¿ëµÈ °ÍÀ¸·Î, º¸Åë 3´ë±â¾Ð Á¤µµ·Î °¡¾ÐµÈ °í¾Ð»ê¼Ò½ÇÀ̳ª °í¾Ð»ê¼ÒÅÊÅ© ¼Ó¿¡ È¯ÀÚ¸¦ ³õ°í Àü½Å¿¡ »ê¼Ò¸¦ ÈíÀÔ½ÃŲ´Ù. °í¾Ð½ÇÀº Å©°í ÀÛÀº ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç, ±¸Á¶»ó 1½Ç½Ä-2½Ç½Ä-´Ù½Ç½ÄÀÌ ÀÖ´Ù. °¡¾Ð °¡½ºÀÇ Á¾·ù¿¡´Â »ê¼Ò-°ø±â-È¥ÇÕ °¡½ºµîÀÌ ÀÖ°í, 2~3 ´ë±â¾Ð ¶Ç´Â ±× ÀÌ»óÀÇ °í¾Ð È¯°æÀ» ¸¸µç´Ù. ÀÓ»óÀûÀ¸·Î ÀÀ¿ë¹üÀ§°¡ ³Ð¾î¼­ ±â°èÀû È¿°ú¿¡ ÀÇÇÏ¿© Àá¼öºÎº´À̳ª Ã¢ÀÚ°ü¸¶ºñ¿¡ ÀÇÇѠâÀÚÆó»ö Ä¡·á µî¿¡ À¯È¿Çϰí, °¡½º±ËÀú µîÀÇ ¹«»ê¼Ò¼º ¼¼±Õ°¨¿°¿¡¼­µµ ÀÌ¿ëµÈ´Ù. ¶Ç »ê¼Ò¿î¹ÝÈ¿°ú¿¡ ÀÇÇÏ¿© ÀÏ»êȭź¼Ò-½É±Ù°æ»ö-³ú»öÀüÁõ-ÃâÇ÷¼îÅ©¿¡ ÀÇÇÑ ±Þ¼ºÀÇ Á¶Á÷»ê¼Ò°áÇÌÀÇ Ä¡·á¿¡ À¯È¿ÇÏ´Ù. ¶Ç ¾ÏÀÇ ¹æ»ç¼±¿ä¹ý¿¡ º´¿ëÇϸé ÀÌ ¿ä¹ýÀ¸·Î ¾Ï¼¼Æ÷ÀÇ ºÐ¿­ÀÌ ¿Õ¼ºÇØÁ®, ¼¼Æ÷ºÐ¿­ ÁßÀΠ¼¼Æ÷¿¡ ¹æ»ç¼±À» Á¶»çÇÔÀ¸·Î½á ºÐ¿­´É·ÂÀ» ¾ø¾Ö´Â µ¥ À¯È¿ÇÏ¿© °í¾Ð»ê¼ÒÈíÀÔÁ¶»ç¹ýÀ̶ó°í ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • area monitoring
    ±¸¿ª°¨½Ã
  • air monitoring
    ´ë±â°¨½Ã
  • blood glucose monitoring
    Ç÷´ç°¨½Ã
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • fetal monitoring
    žư¨½Ã, žƸð´ÏÅ͸µ
  • hemodynamic monitoring
    Ç÷¿ªÇа¨½Ã, Ç÷¿ªÇиð´ÏÅ͸µ
  • invasive monitoring
    ħ½À°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
  • intraoperative monitoring
    ¼ö¼úÁß°¨½Ã
  • monitoring
    °¨½Ã, ¸ð´ÏÅ͸µ
  • metabolic monitoring
    ´ë»ç·®Á¶»ç
  • neuromuscular monitoring
    ½Å°æ±Ù(À°)°¨½Ã
  • noninvasive monitoring
    ºñħ½À°¨½Ã
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • monitoring
    °¨½Ã
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • therapy
    ¿ä¹ý
  • acetylsalycylic acid antiplatelet therapy
    Ç×Ç÷¼ÒÆÇ¿ä¹ý
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • antibiotic therapy
    Ç×»ýÁ¦¿ä¹ý
  • ASA antiplatelet therapy
    (¢¡acetylsalycylic acid antiplatelet therapy) Ç×Ç÷¼ÒÆÇ¿ä¹ý
  • behavioral therapy
    Çൿ¿ä¹ý
  • electroconvulsive therapy
    Àü±â°æ·Ã¿ä¹ý
  • estrogen replacement therapy
    ¿©¼ºÈ£¸£¸ó´ëü¿ä¹ý
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • home oxygen therapy
    °¡Á¤»ê¼Ò¿ä¹ý
  • initial therapy
    ÃʱâÄ¡·á
  • O2 therapy
    »ê¼Ò¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý°¨½Ã
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º°Ë»ç
  • air monitoring
    ´ë±â°¨½Ã
  • area monitoring
    ±¸¿ª°¨½Ã
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • fetal monitoring
    žư¨½Ã
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
  • intraoperative monitoring
    ¼ö¼úÁß°¨½Ã
  • invasive monitoring
    ħ½À°¨½Ã
  • monitoring
    °¨½Ã
  • metabolic monitoring
    ´ë»ç·®Á¶»ç
  • neuromuscular monitoring
    ½Å°æ±ÙÀ°°¨½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • heparin cofactor II
    ÇìÆÄ¸°º¸Á¶ÀÎÀÚ II
  • heparin complement
    ÇìÆÄ¸°º¸Ã¼.
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • air monitoring
    ´ë±â¿À¿°°¨½Ã(ËÀË»ËçËç˧Ëà).
  • area monitoring
    ±¸¿ª<¹æ»çÇÇÆø>°¨½Ã.
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
  • personal monitoring
    °³ÀÎ (ÇÇÆø)°¨½Ã
  • personal monitoring
    °³Àμ±·®°¨½Ã
  • quality monitoring
    Á¤µµ°ü¸®°¨½Ã
  • radiation monitoring
    ¹æ»ç¼±°¨½Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • heparin cofactor II
    ÇìÆÄ¸°º¸Á¶ÀÎÀÚ II
  • heparin complement
    ÇìÆÄ¸°º¸Ã¼.
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • thrombocytopenia induced by heparin
    ÇìÆÄ¸°À¯Àμº Ç÷¼ÒÆÇ°¨¼ÒÁõ
  • air monitoring
    ´ë±â¿À¿°°¨½Ã(ËÀË»ËçËç˧Ëà).
  • area monitoring
    ±¸¿ª<¹æ»çÇÇÆø>°¨½Ã.
  • behavior monitoring program
    Çൿ(ÇàÅÂ)°¨½ÃÇÁ·Î±×·¥
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • fetal monitoring
    žư¨½Ã.
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • individual monitoring
    °³Àθð´ÏÅ͸µ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malarial therapy
    ¸»¶ó¸®¾Æ¿ä¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • selected ion monitoring
    ¼±ÅÃ(àÔ÷É) À̿ ¸ð´ÏÅ͹ý(Ûö)
  • single-ion monitoring
    ´Ü(Ó¤)À̿ ¸ð´ÏÅ͸µ
  • antidotal therapy
    Ç×ÇØµ¶Ä¡·á(ù÷ú°Ô¸ö½Öû)
  • enzyme replacement therapy
    È¿¼Ò ´ëü Ä¡·á (ý£áÈÓÛôðö½Öû)
  • enzyme therapy
    È¿¼ÒÄ¡·á (ý£áÈö½Öû)
  • gene therapy
    À¯ÀüÀÚ Ä¡·á(ë¶îîí­ö½Öû)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°
  • monitoring
    °¨½Ã
  • personal monitoring
    °³ÀÎ(ÇÇÆø)°¨½Ã
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • isotope therapy
    µ¿À§¿ø¼ÒÄ¡·á
  • maintenance therapy
    À¯Áö¿ë¹ý
  • percutaneous ethanol injection therapy
    °æÇÇÀû¿¡Å¸³îÁÖÀÔ¿ä¹ý
  • radiation therapy
    ¹æ»ç¼±Ä¡·á
  • radium therapy
    ¶óµãÄ¡·á
  • replacement therapy
    º¸»ó¿ä¹ý, ´ëÄ¡¿ä¹ý
  • therapy
    Ä¡·á, ¿ä¹ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
IT immunological test; immunotherapy; implantation test; individual therapy; information technology; in...
MT magnetization transfer; malaria therapy; malignant teratoma; mammary tumor; mammilothalamic tract; m...
GT gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm...
RT radiologic technologist; radiotelemetry; radiotherapy; radium therapy; rapid tranquilization; reacti...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LMW heparin Low Molecular Weight heparin
ABPM Ambulatory BP monitoring
ABPM Ambulatory Blood Pressure Monitoring
AEM Ambulatory Electrocardiographic Monitoring
AIMS Australian Incident Monitoring Study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • heparin sulfate
    ÇìÆÄ¸° ¼³ÆäÀÌÆ®
    Ȳ»ê ÇìÆÄ¸®Æ¾.
  • ambulatory ventricular function monitoring
    º¸Çà ½Ã ½É½Ç±â´É °¨½Ã
  • length monitoring system
    ±æÀÌ °¨Áö°è
  • monitoring device
    °¨½Ã ÀåÄ¡
  • monitoring instrument
    °¨½Ã ±â±¸
  • acrylic splint therapy
    ¾ÆÅ©¸± ¾ÈÁ¤ ±³ÇÕ»ó Ä¡·á
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
  • adaptive radiation therapy
    ÀûÀÀ ¹æ»ç¼± Ä¡·á, ¼øÀÀ ¹æ»ç¼± Ä¡·á
  • adjunctive therapy
    ºÎ°¡ ¿ä¹ý
    ÁÖµÈ Ä¡·á °úÁ¤ ÀÌ¿ÜÀÇ Ãß°¡ Ä¡·á °úÁ¤.
  • adjuvant therapy
    º¸Á¶ ¿ä¹ý
  • anticoagulant therapy
    Ç×ÀÀ°í Ä¡·á, Ç×ÀÀ°í ¿ä¹ý
  • antimicrobial therapy
    Ç×±Õ ¿ä¹ý
  • atropine therapy
    ¾ÆÆ®·ÎÇÉ Ä¡·á, ¾ÆÆ®·ÎÇÉ ¿ä¹ý
  • aversion therapy
    Çø±â¿ä¹ý
    ¿øÇÏÁö ¾Ê´Â Çൿ ÆÐÅÏÀ» ºÒÄèÇÑ Àڱذú °áºÎ½ÃŰ´Â °Í. ¶Ç´Â ¿øÇÏÁö ¾Ê´Â ÇàÀ§·ÎºÎÅÍ ºÒÄèÇÑ ÀÚ±ØÀÌ »ý±âµµ·Ï ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ Ä¡·á.
  • behavior therapy
    Çൿ ¿ä¹ý, Çൿ Ä¡·á
    Á¤½Å°úÀû Ä¡·á ¹æ¹ýÀÇ Çϳª. ¹«ÀǽÄÀûÀÎ ¿ä¼Ò³ª ³»ºÎ °¥µî µîÀÇ ´«¿¡ º¸ÀÌÁö ¾Ê´Â °ÍÀ» ´ë»óÀ¸·Î ÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó Á÷Á¢ °üÂûÇÒ ¼ö ÀÖ´Â ÇൿÀ» ´ë»óÀ¸·Î Ä¡·áÇÑ´Ù. ƯÁ¤ ȯ°æÀ» ¼³Á¤Çϰí À̰Ϳ¡ ´ëÇØ¼­ ¹Ù¶÷Á÷ÇÑ ÇൿÀ» ÇÏ°Ô ¸¸µé¾î º¯È­½ÃŰ°í ½ÍÀº ÇൿÀ» °íÃijª°¡´Â ¹æ¹ýÀÌ´Ù. ÇнÀ ÀÌ·ÐÀ» ½Å°æÁõÀû ÇൿÀ̳ª ºÎÀûÀÀ Çൿ µîÀÇ ÀÌ»ó Çൿ¿¡ Àû¿ëÇϰí Çൿ º¯¿ëÀ» ²ÒÇÏ·Á´Â ÀÓ»ó½É¸®ÇÐÀû Ä¡·á¹ýÀÇ ÃÑĪ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
heparin <drug> Sulphated mucopolysaccharide, found in granules of mast cells, that inhibits the action of thrombin on fibrinogen by potentiating antithrombins, thereby interfering with the blood clotting cascade. Platelet factor IV will neutralise heparin.
(18 Nov 1997)
heparin antagonists Coagulant substances inhibiting the anticoagulant action of heparin.
(12 Dec 1998)
heparin binding growth factor <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells.
Synonym: heparin binding growth factor.
Acronym: FGF
(18 Nov 1997)
heparin cofactor II <chemical> A sulfated plasma protein with the mw of approximately 66kda. The protein is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.
Pharmacological action: serine proteinase inhibitors.
Chemical name: Heparin cofactor II
(12 Dec 1998)
heparin complement The protein component of heparin in blood.
(05 Mar 2000)
heparin eliminase <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends.
Chemical name: heparin lyase
Registry number: EC 4.2.2.7
(12 Dec 1998)
heparin-glucosamine 3-O-sulfotransferase <enzyme> Reaction: 3'-phosphoadenylylsulfate + heparin-glucosamine = adenosine 3',5'-bisphosphate + heparin glucosamine 3-o-sulfate
Registry number: EC 2.8.2.23
Synonym: glucosaminyl 3-o-sulfotransferase, d-glucosaminyl 3-o-sulfotransferase
(26 Jun 1999)
heparin, low-molecular-weight <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Pharmacological action: anticoagulant, fibrinolytic agent.
(12 Dec 1998)
heparin lyase <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends.
Chemical name: heparin lyase
Registry number: EC 4.2.2.7
(12 Dec 1998)
heparin unit The quantity of heparin required to keep 1 ml of cat's blood fluid for 24 hr at 0°C; it is equivalent approximately to 0.002 mg of pure heparin.
Synonym: Howell unit.
(05 Mar 2000)
biological monitoring This is the periodic examination of biological specimens for the purposes of monitoring their exposure to or the effects of potentially toxic chemicals to the environment. This is normally done by analysing the amounts of the toxic substances or their metabolites present in body tissues and fluids. The term is also used to mean assessment of the biological status of populations and communities of organisms at risk, in order to protect them and to gain an early warning of possible hazards to human health.
(09 Oct 1997)
blood gas monitoring, transcutaneous The noninvasive measurement or determination of the partial pressure (tension) of oxygen and/or carbon dioxide locally in the capillaries of a tissue by the application to the skin of a special set of electrodes. These electrodes contain photoelectric sensors capable of picking up the specific wavelengths of radiation emitted by oxygenated versus reduced haemoglobin.
(12 Dec 1998)
blood glucose monitoring A way of testing how much glucose (sugar) is in the blood. A drop of blood, usually taken from the fingertip, is placed on the end of a specially coated strip, called a testing strip. The strip has a chemical on it that makes it change colour according to how much glucose is in the blood. A person can tell if the level of glucose is low, high, or normal in one of two ways. The first is by comparing the colour on the end of the strip to a colour chart that is printed on the side of the test strip container. The second is by inserting the strip into a small machine, called a meter, which reads the strip and shows the level of blood glucose in a digital window display. Blood testing is more accurate than urine testing in monitoring blood glucose levels because it shows what the current level of glucose is, rather than what the level was an hour or so previously.
(09 Oct 1997)
blood glucose self-monitoring Self evaluation of whole blood glucose levels outside the clinical laboratory. A digital or battery-operated reflectance meter may be used. It has wide application in controlling unstable insulin-dependent diabetes.
(12 Dec 1998)
blood pressure monitoring, ambulatory Method in which prolonged blood pressure readings are made while the patient undergoes normal daily activities. It allows quantitative analysis of the high blood pressure load over time, can help distinguish between types of hypertension, and can assess the effectiveness of antihypertensive therapy.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin
    ÇìÆÄ¸°;(°£ÀåÀ̳ª ÆóÀÇ Ç÷¾× ÀÀ°í¸¦ ¸·´Â ¹°Áú)
  • radio monitoring
    ÀüÆÄ °¨½Ã
  • therapy
    Ä¡·á; ¿ä¹ý
  • Xray therapy
    ¿¢½º¼± ¿ä¹ý
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cellar therapy
    =CELL THERAPY
  • deep therapy
    ½ÉºÎ X¼± Ä¡·á(ÁÖ´ë»óÀº ¾Ç¼º Á¾¾ç)
  • electric shock therapy
    (Á¤ÀÇ)Àü±â ¼îÅ©¿ä¹ý
  • electroconvulsive therapy
    =ELECTROSHOCK THERAPY
  • electroshock therapy
    (Á¤ÀÇ)Àü±â ¼îÅ©(Ãæ°Ý)¿ä¹ý
  • family therapy
    °¡Á· ¿ä¹ý
  • fever therapy
    ¹ß¿­ ¿ä¹ý
  • fever therapy
    ¹ß¿­¿ä¹ý
  • game therapy
    À¯Àü ¿ä¹ý(À¯ÀüÀÚ °øÇп¡ ÀÇÇÑ À¯Àü»óÀÇ °áÇÕÀ» °³¼±)
  • gene therapy
    À¯ÀüÀÚ ¿ä¹ý(°á¼ÕµÈ À¯ÀüÀÚ¸¦ º¸ÃæÇÏ¿© À¯Àüº´À» °íÄ¡´Â ¿ä¹ý)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á